Jens P. P.
- Country
- Germany
- Department
- Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation (Med. Klinik IV)
Research Overview
- (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
- A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan
- Evaluation of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, and Mast Cell Activation Syndrome: A Phase 2 Multicenter Study
Data & Insights
Has run more than one trial at 109 of 284 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating Paroxysmal Nocturnal Hemoglobinuria (PNH), conducting extensive research into novel therapeutic approaches and treatment alternatives. Their work involves evaluating various complement inhibitors and investigating long-term treatment outcomes.
- Complement inhibitor therapies
- Long-term disease management
- Treatment optimization strategies
Oncology Research
Focuses on treating complex central nervous system lymphomas and acute lymphoblastic leukemia. The investigator explores innovative treatment approaches combining chemotherapy with stem cell transplantation and targeted therapies.
- Primary CNS lymphoma treatment
- Philadelphia-chromosome positive ALL
- High-dose chemotherapy protocols
Rare Disease Management
Specializes in treating Systemic Mastocytosis in both its indolent and advanced forms. The investigator evaluates novel therapeutic agents and their efficacy in managing disease symptoms and progression.
- Advanced Systemic Mastocytosis
- Indolent Systemic Mastocytosis
- Novel therapeutic approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.